CureVac

Industry / private company


Location: Tübingen, Germany (DE) DE

ISNI: 0000000453454022

ROR: https://ror.org/02q3n2241

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Phase i study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma (2025) Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, Krauss J, et al. Journal article IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL (2021) Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, et al. Conference contribution Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 (2021) Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, Mohr P, et al. Conference contribution A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors (2018) Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, et al. Conference contribution